Want to see CVRX full AI Analyst Report?
Top Page
CVRx
(NASDAQ:CVRX)
Select Model
Select Model
Rating:49Neutral
Price Target:
$6.00
▲(26.58% Upside)
Action:Reiterated
Date:08/07/26
The score is held back primarily by weak financial performance—persistent losses, ongoing cash burn, and a more pressured capital structure despite strong revenue growth and high gross margins. Technicals are modestly supportive in the near term, while the earnings call was mixed: progress in reimbursement and margins was outweighed by lowered revenue guidance, execution challenges, and legal/regulatory risk.
Positive Factors
High gross margins and revenue growth
Consistent top-line growth with mid‑to‑high‑80s gross margins indicates attractive unit economics for the Barostim system. Durable high margins mean future incremental revenue can flow to operating leverage, supporting long‑term profitability once fixed SG&A and scale inefficiencies are addressed.
Negative Factors
Weak cash generation and rising leverage
Persistent negative operating and free cash flow combined with materially higher debt raises refinancing and dilution risk. A weakened capital structure limits strategic flexibility, increases cost of capital and could force dilutive raises before the business reaches sustainable positive cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins and revenue growth
Consistent top-line growth with mid‑to‑high‑80s gross margins indicates attractive unit economics for the Barostim system. Durable high margins mean future incremental revenue can flow to operating leverage, supporting long‑term profitability once fixed SG&A and scale inefficiencies are addressed.
Read all positive factors
CVRx (CVRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$137.32M
Dividend YieldN/A
Average Volume (3M)197.28K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth11.73%
EPS Growth8.07%
CountryUS
Employees223
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.98
Shares Outstanding26,535,944
10 Day Avg. Volume162,574
30 Day Avg. Volume197,283
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)4.71
Price to Sales (P/S)3.27
P/FCF Ratio-4.54
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.50Price Target Upside-5.06% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-1.96
Revenue Forecast (FY)$65.33M
CVRx Business Overview & Revenue Model
Company Description
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advan...
How the Company Makes Money
CVRx generates revenue primarily from selling its Barostim therapy to healthcare providers (typically hospitals and implanting centers). Revenue is generally recognized from the sale of the implantable system and related components (e.g., implanta...
CVRx Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Neutral
The call presented a mix of meaningful commercial and clinical progress (16% Q2 revenue growth, improving margins, strong Medicare payment rates, favorable payer policy from Humana, BENEFIT‑HF trial momentum, and >18 months of cash) alongside material near‑term execution and market access headwinds (lowered full‑year revenue guidance, concentrated sales force turnover and productivity issues, significant denials from a major Medicare Advantage payer, a DOJ civil investigative demand, and a decline in European revenue). Management attributes the issues mainly to execution (onboarding and leadership gaps) and outlined targeted remediation actions, but the guidance cut and legal inquiry are notable negatives.Positive Updates
Quarterly Revenue Growth
Total revenue of $15.7 million in Q2 2026, an increase of $2.1 million or 16% year‑over‑year, driven by U.S. heart failure business expansion.
Negative Updates
Reduced Full‑Year Revenue Guidance
Management lowered full‑year 2026 revenue guidance to $58 million–$60 million and expects Q3 revenue of $13.5 million–$14.5 million, citing a weaker back half driven by commercial execution issues.
Read all updates
Q2-2026 Updates
Positive
Negative
Quarterly Revenue Growth
Total revenue of $15.7 million in Q2 2026, an increase of $2.1 million or 16% year‑over‑year, driven by U.S. heart failure business expansion.
Read all positive updates
Company Guidance
CVRx updated full‑year 2026 guidance to $58–60 million of revenue, 86–87% gross margin and $99–101 million of operating expenses, with Q3 revenue expected at $13.5–14.5 million; this follows Q2 results of $15.7 million revenue (up 16% YoY), $13.7 million gross profit (87% margin), U.S. revenue $14.8 million (up 21%), 466 U.S. revenue units, 258 active implanting centers and 56 U.S. sales territories, alongside R&D of $3.1 million, SG&A of $23.6 million and a net loss of $14.0 million ($0.53/share); the company ended Q2 with $64.6 million cash, expects at least 18 months of runway with $40 million undrawn on the debt facility, and cited improving access metrics including a Q2 Medicare Advantage 30‑day prior authorization approval rate of 60% (vs. 44% in 2025), Humana approvals >90%, and ~96% payment rate for traditional Medicare, while outpatient and inpatient procedure payments are supported around $45,000.CVRx Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
34
Negative
Cash Flow
21
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.19M | 56.65M | 51.29M | 39.30M | 22.47M | 13.04M |
| Gross Profit | 52.99M | 48.34M | 42.96M | 33.04M | 17.47M | 9.40M |
| EBITDA | -44.95M | -46.74M | -54.89M | -38.73M | -40.74M | -40.60M |
| Net Income | -51.97M | -53.31M | -59.97M | -41.20M | -41.43M | -43.08M |
Balance Sheet | ||||||
| Total Assets | 92.28M | 104.79M | 133.41M | 115.23M | 124.94M | 152.55M |
| Cash, Cash Equivalents and Short-Term Investments | 64.59M | 75.71M | 105.93M | 90.57M | 106.19M | 142.07M |
| Total Debt | 59.02M | 50.79M | 50.43M | 30.61M | 7.09M | 0.00 |
| Total Liabilities | 72.33M | 65.47M | 62.36M | 39.28M | 15.76M | 6.59M |
| Stockholders Equity | 19.95M | 39.32M | 71.06M | 75.95M | 109.18M | 145.96M |
Cash Flow | ||||||
| Free Cash Flow | -53.34M | -40.75M | -40.51M | -39.61M | -43.36M | -28.91M |
| Operating Cash Flow | -52.62M | -40.17M | -39.14M | -39.02M | -42.68M | -27.73M |
| Investing Cash Flow | -719.00K | -580.00K | -1.36M | -591.00K | -685.00K | -1.18M |
| Financing Cash Flow | 19.50M | 10.52M | 55.87M | 23.98M | 7.49M | 111.88M |
CVRx Technical Analysis
Neutral
4.74
Price Trends
5.27
Positive
6.42
Negative
7.25
Negative
Market Momentum
0.06
Negative
62.57
Neutral
92.63
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVRX, the sentiment is Neutral. The current price of 4.74 is below the 20-day moving average (MA) of 5.19, below the 50-day MA of 5.27, and below the 200-day MA of 7.25, indicating a neutral trend. The MACD of 0.06 indicates Negative momentum. The RSI at 62.57 is Neutral, neither overbought nor oversold. The STOCH value of 92.63 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CVRX.
CVRx Risk Analysis
CVRx disclosed 55 risk factors in its most recent earnings report. CVRx reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CVRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | $337.25M | 33.39 | 22.14% | ― | 16.79% | 45.17% | |
67 Neutral | $447.39M | 30.15 | 10.66% | ― | 23.10% | 22.75% | |
59 Neutral | $60.29M | 32.56 | 3.68% | ― | -0.32% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $137.32M | -2.56 | -120.77% | ― | 11.73% | 8.07% | |
49 Neutral | $174.63M | -7.09 | -12.90% | ― | 3.39% | 19.78% | |
46 Neutral | $68.20M | -0.86 | -51.88% | ― | 25.74% | -26.25% |
* Healthcare Sector Average
CVRX
CVRx
5.94
-1.00
-14.41%
ELMD
Electromed
42.04
23.39
125.42%
INGN
Inogen
6.49
0.62
10.56%
XTNT
Xtant Medical Holdings
0.44
-0.19
-29.62%
VMD
Viemed Healthcare
9.52
2.56
36.78%
NNOX
Nano-X Imaging
1.02
-3.60
-77.92%
CVRx Corporate Events
Business Operations and StrategyExecutive/Board Changes
CVRx CFO Announces Resignation and Leadership Transition Plan
Neutral
Jun 9, 2026
On June 7, 2026, CVRx Chief Financial Officer Jared Oasheim notified the company of his plan to resign to pursue other opportunities, with an orderly transition that keeps him in the CFO role until a successor starts and employed full-time at leas...
Executive/Board ChangesShareholder Meetings
CVRx Shareholders Reelect Directors and Ratify Auditor
Positive
Jun 3, 2026
On June 1, 2026, CVRx, Inc. held its 2026 annual meeting of stockholders, where shareholders elected three Class II directors, Michael Dale, Kevin Hykes, and Joseph Slattery, to serve terms extending until the 2029 annual meeting. The voting resul...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.